Stable Pharmaceutical formulation comprising an Antibody (anti Human Delta ligand Dll4 type 4)； and a kit comprising the composition in Packaging and instructions.
The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.La solicitud describe formulaciones estabilizadas de un anticuerpo anti ligando tipo delta 4 humano, mediante un amortiguador, un cosolvente orgánico y un estabilizador térmico, con el obetivo de que mantengan su viscosidad para la administración intravenosa en pacientes.
